Beyond Platinum: Current Approaches to Advanced Bladder Cancer

Sunday, November 17, 2024

10:35 AM – 11:20 AM CT

Location: Grapevine Ballroom

CE: 0.75 credits/hours

Speaker(s)

Saneese K. Stephen, MPAS, PA-C

HAL GUMO APP Supervisor
The University of Texas MD Anderson Cancer Center
Arlene O. Siefker-Radtke, MD (she/her/hers)

Professor
The University of Texas MD Anderson Cancer Center
Pearland, Texas, United States

Disclosures:

Saneese K. Stephen has no relevant financial relationships to disclose.
Arlene Siefker-Radtke has served on advisory boards for AbbVie, Astellas, AstraZeneca, Basilea, Bicycle Therapeutics, Bristol Myers Squibb, Genentech, G1 Therapeutics, Gilead, Ideeya Biosciences, Immunomedics, Janssen, Loxo, Merck, Mirati, Nektar Therapeutics, Seattle Genetics, and Taiho.

Learning Objectives:

Recall appropriate biomarker/molecular tests to inform treatment planning for patients with advanced/metastatic urothelial carcinoma (mUC) who may be eligible for targeted therapy
Evaluate the latest clinical data on safety and efficacy of currently recommended first- and second-line regimens for advanced/metastatic urothelial carcinoma
Identify antibody-drug conjugates, targeted small molecules, and immune checkpoint inhibitors by their mechanisms of action, and the latest clinical data for their safety and efficacy in mUC
Employ interprofessional strategies to monitor for and mitigate adverse events associated with recently approved therapies for mUC
Improve supportive care services provided to patients with poor performance status and multiple comorbidities